ARFGEF2

Across TCGA pan-cancer cohorts, ARFGEF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARFGEF2 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ARFGEF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARFGEF2 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

COAD, LSCC, and CCRCC are the cancer types where ARFGEF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	1.000	0.910	.011	66	view →
LSCC	DFS	Quartile	II,III,IV	0.444	0.890	.001	30	view →
CCRCC	DFS	Quartile	III,IV	0.520	0.922	.014	16	view →
UCEC	OS	Median	III,IV	1.000	0.433	.007	10	view →
HNSC	DFS	Median	III,IV	0.939	1.000	.043	1	view →
LUAD	DFS	Quartile	All	0.697	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARFGEF2–COAD (DFS)

Open the COAD breakdown →